COMPANY
Lumen Bioscience
Since the raise (Oct 8, 2025): 1 of 1 open job was first seen after it.
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Process Engineer II - GMP Equipment Lifecycle | Seattle, WA | Aug 27, 2026 | Oct 5, 2026 |
Raises and deals from press releases
- Raise Series C · $30M · announced Oct 8, 2025 Company release ↗
Source quote
- Oct 8, 2025 · Company release ↗
“Lumen Bioscience raises $30M Series C extension”
- Oct 8, 2025 · Company release ↗
Timeline
- Trial start Phase 1: A Study of Intranasal LMN-1001 in Healthy Adults source ↗
- Board tracked Radar started tracking this company’s job board (1 open job at last check). source ↗
- Raise Private equity round — Series C extension: $30M (total, as published), announced Oct 8, 2025. Source: company's own press page. source ↗
- Raise Series C · $30M source ↗
- Trial start Early phase 1: G.I. Pharmacokinetics of LMN-401 in Individuals With Ileostomies source ↗
- Trial start Phase 2/Phase 3: LMN-201 for Prevention of C. Difficile Infection Recurrence source ↗
- Trial start —: Etiology of Travelers' Diarrhea in Australian Tourists Traveling to Southeast Asia source ↗
- Trial start Phase 1: A Study to Determine the Tolerability of Intranasal LMN-301 source ↗
- Trial start Phase 2: LMN-101 in a Campylobacter Human Challenge Model source ↗
- Trial start Phase 1: Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies source ↗
- Trial start Phase 1: Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers source ↗
Upcoming milestones
- Jun 6, 2027 (ESTIMATED) · Phase 1 · A Study of Intranasal LMN-1001 in Healthy Adults · NCT07852208
Open jobs 1
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Process Engineer II - GMP Equipment Lifecycle | Seattle, WA | Aug 27, 2026 | Oct 5, 2026 | Mid |
Funding
- Private equity round — Series C extension: $30M (total, as published), announced Oct 8, 2025. Source: company's own press page. source ↗
Clinical trials (lead sponsor) 8
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05330182 | LMN-201 for Prevention of C. Difficile Infection Recurrence | Phase 2/Phase 3 | Active, not recruiting | Aug 29, 2024 | Aug 31, 2026 (actual) |
| NCT07852208 | A Study of Intranasal LMN-1001 in Healthy Adults | Phase 1 | Not yet recruiting | Nov 9, 2026 | Jun 6, 2027 (estimated) |
| NCT06363890 | Etiology of Travelers' Diarrhea in Australian Tourists Traveling to Southeast Asia | Not listed | Completed | Jun 20, 2024 | Mar 1, 2026 (actual) |
| NCT04182490 | LMN-101 in a Campylobacter Human Challenge Model | Phase 2 | Completed | Feb 21, 2022 | Oct 4, 2022 (actual) |
| NCT06030414 | A Study to Determine the Tolerability of Intranasal LMN-301 | Phase 1 | Completed | Oct 6, 2023 | Dec 28, 2023 (actual) |
| NCT04893239 | Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies | Phase 1 | Completed | Aug 18, 2021 | Feb 23, 2022 (actual) |
| NCT04098263 | Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers | Phase 1 | Completed | Nov 15, 2019 | Apr 15, 2020 (actual) |
| NCT06556940 | G.I. Pharmacokinetics of LMN-401 in Individuals With Ileostomies | Early phase 1 | Recruiting | Dec 4, 2024 | Oct 2, 2025 (estimated) |
NIH awards 5
- NIH award 5R42AI138623-05 FY2024: $925,300 awarded for that fiscal year; activity R42 (STTR); PI KHUONG, NHI; recipient as written: LUMEN BIOSCIENCE, INC., SEATTLE, WA. Phase II STTR development of an intranasal/oral source ↗
- NIH award 5R42AI138623-04 FY2023: $1,000,000 awarded for that fiscal year; activity R42 (STTR); PI KHUONG, NHI; recipient as written: LUMEN BIOSCIENCE, INC., SEATTLE, WA. Phase II STTR development of an intranasal/or source ↗
- NIH award 2R42AI138623-03A1 FY2021: $1,000,000 awarded for that fiscal year; activity R42 (STTR); PI KHUONG, NHI; recipient as written: LUMEN BIOSCIENCE, INC., SEATTLE, WA. Phase II STTR development of an intranasal/ source ↗
- NIH award 5R41AI138623-02 FY2019: $297,071 awarded for that fiscal year; activity R41 (STTR); PI MURPHY, SEAN C; recipient as written: LUMEN BIOSCIENCE, INC., SEATTLE, WA. Development of a Spirulina-based oral malari source ↗
- NIH award 1R41AI138623-01A1 FY2018: $299,904 awarded for that fiscal year; activity R41 (STTR); PI MURPHY, SEAN C; recipient as written: LUMEN BIOSCIENCE, INC., SEATTLE, WA. Development of a Spirulina-based oral mala source ↗
Connect
See your connections at Lumen Bioscience on LinkedIn (search by name, results not checked)